Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Influenza vaccination in healthy working adults in Russia

Observational study of effectiveness and return on investment for the employer

  • 194 Accesses

  • 7 Citations

Abstract

Background

All age groups are affected by influenza infection, resulting in significant medical and economic burden. Influenza infection of healthy working adults can have a marked effect on companies due to lost work days and reduced productivity. Studies in corporate settings have shown that vaccination programmes reduce this burden, although there is a lack of data in Eastern European countries.

Objectives

To determine the effectiveness of influenza vaccination in healthy working adults in Russia and the economic benefits of such a programme from an employer’s perspective.

Methods

In a prospective, non-randomized, non-placebo-controlled, observational study, healthy vaccinated and unvaccinated adults employed at the Russian Railways Public Corporation were followed for 8 months during the 2005–6 influenza season using questionnaires. A first questionnaire was administered at inclusion to collect general employee information; a second questionnaire was administered to collect data on post-vaccination adverse events; and monthly questionnaires were used to gather data on influenza-like illness (ILI). Effectiveness calculations and cost analyses were performed to evaluate the impact of the influenza vaccination programme on employee productivity and costs for the employer. The study vaccine used was the trivalent, inactivated, split vaccine Vaxigrip® (sanofi pasteur, France).

Results

A total of 1331 employees volunteered for the study: 701 were vaccinated and 630 were not. The vaccine effectiveness was 70.4% against ILI events and 80.8% against sick leave days. Assuming that employees working with ILI symptoms had a reduced level of productivity (30–70% of normal), cost savings per vaccinated employee ranged from €2.13 to €5.43.

Conclusions

This study showed that an influenza vaccination programme significantly reduced ILI episodes and absenteeism, and may provide a positive return on investment for the employer.

This is a preview of subscription content, log in to check access.

Table I
Table II
Table III
Table IV
Fig. 1

References

  1. 1

    Information on infectious and parasitic diseases morbidity in Russian Federation, January–December 2007. Protection Population Social Organization J 2008; 1: 51

  2. 2

    Centers for Disease Control and Prevention. Update: influenza activity. United States, October 1, 2006-February 3, 2007. MMWR 2007; 56(6): 118–21

  3. 3

    Keech M, Beardsworth P. The impact of influenza on working days lost: a review of the literature. Pharmaco-economics 2008; 26(11): 911–24

  4. 4

    Carrat F, Sahler C, Rogez S, et al. Influenza burden of illness: estimates from a national prospective survey of household contacts in France. Arch Intern Med 2002; 162(16): 1842–8

  5. 5

    Centers for Disease Control and Prevention. Influenza activity: United States and worldwide, May 18-September 19, 2008. MMWR 2008; 57(38): 1046–9

  6. 6

    Morales A, Martinez MM, Tasset-Tisseau A, et al. Costs and benefits of influenza vaccination and work productivity in a Colombian company from the employer’s perspective. Value Health 2004; 7(4): 433–41

  7. 7

    Keech M, Scott AJ, Ryan PJ. The impact of influenza and influenza-like illness on productivity and healthcare resource utilization in a working population. Occup Med (Lond) 1998; 48(2): 85–90

  8. 8

    Beketov AS, Belousov DU, Bojko EA, et al. Economical analysis of vaccination against flu in children and adolescents [in Russian]. Russian Med J 2007; 15(22): 1681–5

  9. 9

    WHO. Influenza vaccines: WHO position paper. Wkly Epidemiol Rec 2005 Aug 19; 33

  10. 10

    Postma MJ, Jansema P, van Genugten ML, et al. Pharmacoeconomics of influenza vaccination for healthy working adults: reviewing the available evidence. Drugs 2002; 62(7): 1013–24

  11. 11

    Burckel E, Ashraf T, de Sousa Filho JP, et al. Economic impact of providing workplace influenza vaccination: a model and case study application at a Brazilian pharma-chemical company. Pharmacoeconomics 1999; 16(5 Pt 2): 563–76

  12. 12

    Tasset-Tisseau A, Plun-Favreau J, Turan E, et al. Influenza corporate vaccination programs: an international modelling approach. Int Congr Ser 2004; 1263: 600–4

  13. 13

    Bridges CB, Thompson WW, Meltzer MI, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA 2000; 284(13): 1655–63

  14. 14

    Millot JL, Aymard M, Bardol A. Reduced efficiency of influenza vaccine in prevention of influenza-like illness in working adults: a 7 month prospective survey in EDF Gaz de France employees, in Rhone-Alpes, 1996–1997. Occup Med (Lond) 2002; 52(5): 281–92

  15. 15

    Ito Y, Sumi H, Kato T. Evaluation of influenza vaccination in health-care workers, using rapid antigen detection test. J Infect Chemother 2006; 12(2): 70–2

  16. 16

    King Jr JC, Cummings GE, Stoddard J, et al. A pilot study of the effectiveness of a school-based influenza vaccination program. Pediatrics 2005; 116(6): e868–73

  17. 17

    Wood SC, Alexseiv A, Nguyen VH. Effectiveness and economical impact of vaccination against influenza among a working population in Moscow. Vaccine 1999; 17(Suppl. 3): S81–7

  18. 18

    Federal Service on Customers’ Rights. Protection and human well-being surveillance [online]. Available from URL: http://www.rospotrebnadzor.ru [Accessed 2009 Aug 1]

  19. 19

    Campbell DS, Rumley MH. Cost-effectiveness of the influenza vaccine in a healthy, working-age population. J Occup Environ Med 1997; 39(5): 408–14

  20. 20

    Marinich IG, Timonshenko OF, Ignatieva GS, et al. Mortality rate in patients with flu, other respiratory infections and acute penumonia in St. Peterburg [in Russian]. Vakcinacia 1999; 5: 4–6

  21. 21

    Jefferson TO, Rivetti D, Di PC, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2007; (2): CD001269

  22. 22

    Burtseva EI, Slepushkin AN, Vlasova LN, et al. Comparative evaluation of the reactogenicity and immunogenicity of inactivated influenza vaccines in the elderly [in Russian]. Zh Mikrobiol Epidemiol Immunobiol 2000 Sep-Oct; (5): 40–5

  23. 23

    Burtseva EI, Slepushkin AN, Vlasova LN, et al. Efficacy of inactivated influenza vaccines in the elderly [in Russian]. Vakcinacia 2000; 11: 8–9

  24. 24

    Ramadan PA, de Araujo FB, Ferreira JM. A 12-month follow-up of an influenza vaccination campaign based on voluntary adherence: report on upper-respiratory symptoms among volunteers and non-volunteers. Sao Paulo Med J 2001; 119(4): 142–5

  25. 25

    Dille JH. A worksite influenza immunization program: impact on lost work days, health care utilization, and health care spending. AAOHN J 1999; 47(7): 301–9

  26. 26

    Nichol KL. Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza. Arch Intern Med 2001; 161(5): 749–59

  27. 27

    Nichol KL, Lind A, Margolis KL, et al. The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med 1995; 333(14): 889–93

  28. 28

    Samad AH, Usul MH, Zakaria D, et al. Workplace vaccination against influenza in Malaysia: does the employer benefit? J Occup Health 2006; 48(1): 1–10

  29. 29

    Cohen P, Darling C, Hampson A, et al. Influenza vaccination in an occupational setting: effectiveness and cost-benefit study. J Occup Health Safety 2003; 19(2): 167–82

  30. 30

    Grotto I, Mandel Y, Green MS, et al. Influenza vaccine efficacy in young, healthy adults. Clin Infect Dis 1998; 26(4): 913–7

  31. 31

    Carrat F, Tachet A, Rouzioux C, et al. Evaluation of clinical case definitions of influenza: detailed investigation of patients during the 1995–1996 epidemic in France. Clin Infect Dis 1999; 28(2): 283–90

  32. 32

    Blank PR, Scwenkglenks M, Szucs TD. Vaccination coverage rates in eleven European countries during two consecutive influenza seasons. J Infect 2009; 58(6): 446–58

  33. 33

    Goldmann DA. Transmission of viral respiratory infections in the home. Pediatr Infect Dis J 2000; 19(10 Suppl.): S97–102

  34. 34

    Centers for Disease Control and Prevention. Outbreak of influenza A infection among travelers: Alaska and the Yukon Territory, May-June 1999. MMWR Morb Mortal Wkly Rep 1999; 48(25): 545–6, 555

  35. 35

    Glezen WP. Herd protection against influenza. J Clin Virol 2006; 37(4): 237–43

  36. 36

    Hogan H. Flu vaccinations: are they worth the cost? Occup Health 1993; 15: 21–2

Download references

Acknowledgements

The study was funded by sanofi pasteur, Lyon, France, and Laure Durand is an employee of the company. Data collection, management and analysis were performed by the RRPC. The authors thank Olga Lyabis and Alexander Loguinov, formerly of sanofi pasteur, Russia, for their involvement in this project. The authors take full responsibility for the content of this article, and thank Lisa Lovelidge of Hermes Medical Communications Ltd (supported by sanofi pasteur, France) for her assistance in preparing the first draft of the manuscript and thereafter collating the comments of the authors.

Author information

Correspondence to Dr Laure Durand.

Electronic supplementary material

Rights and permissions

Reprints and Permissions

About this article

Cite this article

At’kov, O.Y., Azarov, A.V., Zhukov, D.A. et al. Influenza vaccination in healthy working adults in Russia. Appl Health Econ Health Policy 9, 89–99 (2011). https://doi.org/10.2165/11538680-000000000-00000

Download citation

Keywords

  • Influenza
  • Sick Leave
  • Influenza Vaccination
  • Influenza Season
  • Influenza Infection